These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 22827572)

  • 1. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK).
    Axten JM; Medina JR; Feng Y; Shu A; Romeril SP; Grant SW; Li WH; Heerding DA; Minthorn E; Mencken T; Atkins C; Liu Q; Rabindran S; Kumar R; Hong X; Goetz A; Stanley T; Taylor JD; Sigethy SD; Tomberlin GH; Hassell AM; Kahler KM; Shewchuk LM; Gampe RT
    J Med Chem; 2012 Aug; 55(16):7193-207. PubMed ID: 22827572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones.
    Beckers T; Sellmer A; Eichhorn E; Pongratz H; Schächtele C; Totzke F; Kelter G; Krumbach R; Fiebig HH; Böhmer FD; Mahboobi S
    Bioorg Med Chem; 2012 Jan; 20(1):125-36. PubMed ID: 22169601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
    Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
    Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.
    Ishikawa T; Seto M; Banno H; Kawakita Y; Oorui M; Taniguchi T; Ohta Y; Tamura T; Nakayama A; Miki H; Kamiguchi H; Tanaka T; Habuka N; Sogabe S; Yano J; Aertgeerts K; Kamiyama K
    J Med Chem; 2011 Dec; 54(23):8030-50. PubMed ID: 22003817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.
    Certal V; Carry JC; Halley F; Virone-Oddos A; Thompson F; Filoche-Rommé B; El-Ahmad Y; Karlsson A; Charrier V; Delorme C; Rak A; Abecassis PY; Amara C; Vincent L; Bonnevaux H; Nicolas JP; Mathieu M; Bertrand T; Marquette JP; Michot N; Benard T; Perrin MA; Lemaitre O; Guerif S; Perron S; Monget S; Gruss-Leleu F; Doerflinger G; Guizani H; Brollo M; Delbarre L; Bertin L; Richepin P; Loyau V; Garcia-Echeverria C; Lengauer C; Schio L
    J Med Chem; 2014 Feb; 57(3):903-20. PubMed ID: 24387221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.
    Koehler MF; Bergeron P; Blackwood E; Bowman KK; Chen YH; Deshmukh G; Ding X; Epler J; Lau K; Lee L; Liu L; Ly C; Malek S; Nonomiya J; Oeh J; Ortwine DF; Sampath D; Sideris S; Trinh L; Truong T; Wu J; Pei Z; Lyssikatos JP
    J Med Chem; 2012 Dec; 55(24):10958-71. PubMed ID: 23199076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
    Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG
    Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.
    Menichincheri M; Albanese C; Alli C; Ballinari D; Bargiotti A; Caldarelli M; Ciavolella A; Cirla A; Colombo M; Colotta F; Croci V; D'Alessio R; D'Anello M; Ermoli A; Fiorentini F; Forte B; Galvani A; Giordano P; Isacchi A; Martina K; Molinari A; Moll JK; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pillan A; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Vianello P; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2010 Oct; 53(20):7296-315. PubMed ID: 20873740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.
    Li X; Wang A; Yu K; Qi Z; Chen C; Wang W; Hu C; Wu H; Wu J; Zhao Z; Liu J; Zou F; Wang L; Wang B; Wang W; Zhang S; Liu J; Liu Q
    J Med Chem; 2015 Dec; 58(24):9625-38. PubMed ID: 26630553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.
    Zehnder L; Bennett M; Meng J; Huang B; Ninkovic S; Wang F; Braganza J; Tatlock J; Jewell T; Zhou JZ; Burke B; Wang J; Maegley K; Mehta PP; Yin MJ; Gajiwala KS; Hickey MJ; Yamazaki S; Smith E; Kang P; Sistla A; Dovalsantos E; Gehring MR; Kania R; Wythes M; Kung PP
    J Med Chem; 2011 May; 54(9):3368-85. PubMed ID: 21438541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
    Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
    J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.
    Sutherlin DP; Bao L; Berry M; Castanedo G; Chuckowree I; Dotson J; Folks A; Friedman L; Goldsmith R; Gunzner J; Heffron T; Lesnick J; Lewis C; Mathieu S; Murray J; Nonomiya J; Pang J; Pegg N; Prior WW; Rouge L; Salphati L; Sampath D; Tian Q; Tsui V; Wan NC; Wang S; Wei B; Wiesmann C; Wu P; Zhu BY; Olivero A
    J Med Chem; 2011 Nov; 54(21):7579-87. PubMed ID: 21981714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).
    McHardy T; Caldwell JJ; Cheung KM; Hunter LJ; Taylor K; Rowlands M; Ruddle R; Henley A; de Haven Brandon A; Valenti M; Davies TG; Fazal L; Seavers L; Raynaud FI; Eccles SA; Aherne GW; Garrett MD; Collins I
    J Med Chem; 2010 Mar; 53(5):2239-49. PubMed ID: 20151677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer.
    Wei W; Feng Z; Liu Z; Li X; He H; Ran K; Shi Y; Zhu Y; Ye T; Gao C; Wang N; Yu L
    Eur J Med Chem; 2022 Jan; 228():113978. PubMed ID: 34810020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity.
    Atkins C; Liu Q; Minthorn E; Zhang SY; Figueroa DJ; Moss K; Stanley TB; Sanders B; Goetz A; Gaul N; Choudhry AE; Alsaid H; Jucker BM; Axten JM; Kumar R
    Cancer Res; 2013 Mar; 73(6):1993-2002. PubMed ID: 23333938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
    Gangjee A; Lin X; Kisliuk RL; McGuire JJ
    J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
    Sampson PB; Liu Y; Forrest B; Cumming G; Li SW; Patel NK; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Mao G; Plotnikova O; Hodgson R; Beletskaya I; Mason JM; Luo X; Nadeem V; Wei X; Kiarash R; Madeira B; Huang P; Mak TW; Pan G; Pauls HW
    J Med Chem; 2015 Jan; 58(1):147-69. PubMed ID: 25723005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083).
    Zhou HJ; Wang J; Yao B; Wong S; Djakovic S; Kumar B; Rice J; Valle E; Soriano F; Menon MK; Madriaga A; Kiss von Soly S; Kumar A; Parlati F; Yakes FM; Shawver L; Le Moigne R; Anderson DJ; Rolfe M; Wustrow D
    J Med Chem; 2015 Dec; 58(24):9480-97. PubMed ID: 26565666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK).
    Smith AL; Andrews KL; Beckmann H; Bellon SF; Beltran PJ; Booker S; Chen H; Chung YA; D'Angelo ND; Dao J; Dellamaggiore KR; Jaeckel P; Kendall R; Labitzke K; Long AM; Materna-Reichelt S; Mitchell P; Norman MH; Powers D; Rose M; Shaffer PL; Wu MM; Lipford JR
    J Med Chem; 2015 Feb; 58(3):1426-41. PubMed ID: 25587754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.